Pharvaris Netherlands B.V.
Deucrictibant
Hereditary Angioedema (HAE)
Countdown
56days
Phase 3 readout · ~ Aug 31, 2026 estimated
What's at stake
Phase 3 trial results for Deucrictibant in Hereditary Angioedema (HAE) are due ~ Aug 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 13h ago
“CT.gov NCT06669754: Phase 3 trial, sponsor Pharvaris Netherlands B.V., drug Deucrictibant. Primary completion date 2026-08 (estimated).”